Sanofi (EPA:SAN) has been given a €100.00 ($113.64) price target by analysts at UBS Group in a note issued to investors on Wednesday, Borsen Zeitung reports. UBS Group’s price target points to a potential upside of 15.41% from the stock’s previous close.
A number of other research analysts also recently issued reports on SAN. Deutsche Bank Aktiengesellschaft set a €80.00 ($90.91) target price on shares of Sanofi in a research report on Monday, November 1st. The Goldman Sachs Group set a €124.00 ($140.91) target price on shares of Sanofi in a research report on Thursday, November 11th. Sanford C. Bernstein set a €120.00 ($136.36) target price on shares of Sanofi in a research report on Thursday, October 28th. Credit Suisse Group set a €96.00 ($109.09) target price on shares of Sanofi in a research report on Friday, October 29th. Finally, JPMorgan Chase & Co. set a €105.00 ($119.32) target price on shares of Sanofi in a research report on Friday, October 29th. One research analyst has rated the stock with a sell rating, three have issued a hold rating and five have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of €103.45 ($117.56).
EPA:SAN opened at €86.65 ($98.47) on Wednesday. Sanofi has a 12 month low of €63.09 ($71.69) and a 12 month high of €92.97 ($105.65). The firm has a fifty day simple moving average of €85.65 and a 200-day simple moving average of €86.60.
Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through three segments: Pharmaceuticals, Vaccines, and Consumer Healthcare. The company provides specialty care products, including human monoclonal antibodies; products for multiple sclerosis, neurology, other inflammatory diseases, immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes; and cardiovascular and established prescription products.
Featured Story: Secondary Public Offerings
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.